Summary
80.51
-3.62
(-4.30%)
06/05/2026
Dianthus Therapeutics, Inc. (DNTH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -4.30 | -9.99 | -10.78 | 31.06 | 81.90 | 333.55 | -57.25 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Buy |
| P/E | Strong Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 80.51 | |
| Open | 84.03 | |
| High | 85.82 | |
| Low | 79.64 | |
| Volume | 835,900 | |
| Change | -3.62 | |
| Change % | -4.30 | |
| Avg Volume (20 Days) | 598,385 | |
| Volume/Avg Volume (20 Days) Ratio | 1.40 | |
| 52 Week Range | 16.64 - 96.50 | |
| Price vs 52 Week High | -16.57% | |
| Price vs 52 Week Low | 383.83% | |
| Range | -4.19 | |
| Gap Up/Down | -3.39 | |
Profitibility | ||
| Market Capitalization (Mln) | 1,293 | |
| Revenue per share | 0.0278 | |
| Net Income per share | -0.2357 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -341.5275 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/02 16:01 EST - globenewswire.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards...
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards...
05/30 10:06 EST - seekingalpha.com
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
05/26 16:01 EST - globenewswire.com
Dianthus Therapeutics to Participate in Two Investor Conferences
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in...
Dianthus Therapeutics to Participate in Two Investor Conferences
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in...
05/19 15:00 EST - globenewswire.com
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
05/18 13:13 EST - fool.com
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
05/17 14:05 EST - fool.com
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
05/05 22:57 EST - globenewswire.com
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and...
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and...
05/05 18:16 EST - zacks.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.82 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.82 per share a year ago.
05/05 16:01 EST - globenewswire.com
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
04/19 09:08 EST - fool.com
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr.
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr.
04/06 15:27 EST - fool.com
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. The transaction represented 100% of Savitz's direct common stock holdings, reducing direct ownership of this class to zero.
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
114,367 shares were sold for a transaction value of approximately $9.49 million on March 31, 2026. The transaction represented 100% of Savitz's direct common stock holdings, reducing direct ownership of this class to zero.
04/06 04:46 EST - defenseworld.net
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
JPMorgan Chase and Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 626.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,124 shares of the company's stock...
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
JPMorgan Chase and Co. lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 626.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,124 shares of the company's stock...
04/01 04:55 EST - zacks.com
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
03/22 02:30 EST - defenseworld.net
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned...
03/20 01:32 EST - defenseworld.net
SELLAS Life Sciences Group (NASDAQ:SLS) & Dianthus Therapeutics (NASDAQ:DNTH) Critical Survey
SELLAS Life Sciences Group (NASDAQ: SLS - Get Free Report) and Dianthus Therapeutics (NASDAQ: DNTH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends,...
SELLAS Life Sciences Group (NASDAQ:SLS) & Dianthus Therapeutics (NASDAQ:DNTH) Critical Survey
SELLAS Life Sciences Group (NASDAQ: SLS - Get Free Report) and Dianthus Therapeutics (NASDAQ: DNTH - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends,...
03/18 13:48 EST - fool.com
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus.
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus.
03/16 04:52 EST - defenseworld.net
Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $3,559,646.18 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CAO Edward Carr sold 43,682 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with...
Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $3,559,646.18 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CAO Edward Carr sold 43,682 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with...
03/16 04:52 EST - defenseworld.net
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the firm's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a legal...
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the firm's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a legal...
Market News
×
Loading news…